Pricing

The rapid pace of new pharmaceutical approvals raises questions of whether ICER can keep up and maintain the quality and rigor demanded by healthcare audiences, writes Jeremy Schafer.

ISPOR has published its third issue of the top trends in HEOR. Leela Barham takes a look at how the list has changed over time.

In a a new report penned by CEOs, more than 200 biopharma leaders acknowledge that out-of-pocket costs for individuals must be limited to sustain support for fiscal and patent policies key to advancing innovation.

A look at two surveys that reveal payer perspectives regarding current and future management of high-cost durable therapies with one-time administration.

This article discusses how cost differences with other countries reflect income differences, how these differences are typical for cost in medical services, and more.

With employers and the public scrutinizing drug prices like never before, rebates-long at the center of pharma’s market access strategy-may be losing their luster, writes Amber Gilbert.

Pricing in the context of patient access and affordability continues to present problems and constitute a real threat to innovation. Meaningful reform involves rectifying market imperfections in public and private third-party prescription drug payment sectors, writes Robert A. Freeman.

A look at the communication disconnect between contracting with managed care plans and pharmaceutical benefit managers (PBMs) and the imposition and implications of prior authorization (PA) requirements.

In response to growing Institute for Clinical and Economic Review (ICER) activity, Jenny Lee and Eric Latch take a revised look at payer reliance on ICER assessments and perceptions on value-based pricing.

A formal effort is underway in Europe to gather concrete clues on the value of real-world evidence in payer decision-making.

An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.

Realizing the full potential of enabling technologies such as AI and machine learning in measuring treatment value and outcomes.

Industry working group identifies the value characteristics that may, collectively, become part of a higher-level, shared approach to valuing pharmaceutical treatments.

Rick Kelly and Nisha Desai provide an overview of the “American Patients First” blueprint's four key strategies.

Rick Kelly and Nisha Desai review the proposals in the Pharmaceutical Drug Pricing Reduction Act (PDPRA) with the greatest potential impact.

The impacts of disruptive curative therapies and advances in the future of health will be profound. To be best positioned for success, healthcare systems under continuous cost pressure must address three key areas, writes Thomas Unger.

Leela Barham talks to Sir David Haslam, the outgoing Chair of UK’s National Institute for Health and Care Excellence (NICE), about the highs and lows of his six-year tenure at the organization.

The decision to eradicate pharma rebates and prompt direct discounts for federal beneficiaries could, if passed, upend the market-what are the critical questions for new products?

While there are challenges at every turn, the promise of outcomes-based contracting is a level of care for patients that might otherwise not be possible, while striking the right balance of benefits and risks for all parties involved, writes Melonie Warfel.

Its use, new data shows, could boost the economic benefit profile of more “common” drugs-and better inform HTA and payer decision-making.

In the second in a series of articles summarizing efforts to put each of the “American Patients First” blueprint's four strategies into action, Rick Kelly and Nisha Desai focus on “Better Negotiation”.

Cell and gene therapies in crosshairs of pricing focus, prompting stepped-up proposals on ways to finance these products.

The price of a drug need not be, and in fact must not be, the only factor considered when determining its value, writes William Kirsh.

A rule to eradicate drug rebates and prompt direct discounts for federal beneficiaries raises challenging questions for drug manufacturers and other stakeholders.

Ed Schoonveld reviews the key topics discussed at the World Health Organization's second Fair Pricing Forum, held in Johannesburg, South Africa last month.

The UK has had in place what amount to two pricing schemes for branded medicines for years. But with major changes to both schemes set out in 2018, it’s now a new tale of two pricing schemes. Leela Barham reports.

The benefits and challenges of outcomes-based contracting.

Longitudinal databases can have several advantages for pharma companies in comparison to collecting data from clinical trials alone.

Among the new acronyms watch is UPI, or unjustified price increase, recently coined by ICER as part of its new workstream to explore price increases for both branded and generic drugs in the US.

How real-world evidence creates shared value for stakeholders across the healthcare spectrum.